Arcutis Biotherapeutics, Inc. (ARQT) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Q4 profitability ⢠High leverage ARQT combines solid liquidity and a strong Q4 profitability/cashâflow turnaround with persistent FY losses, heavy operating spend and receivables, meaningful leverage and lofty valuation that together limit nearâterm upside.
Price Behavior
Key Price Behavior Insights: ⢠Mild recovery ⢠Neutral momentum ⢠Resistance test Support Level: $21.22 Resistance Level: $24.80 Trading slightly above its last month SMA after a bounce from the lateâMarch low, the stock shows a mild short-term recovery with neutral momentum, a clear resistance near $24.80 (March 9) and support near $21.22 (March 27) where failure to clear resistance risks revisiting support.
Sentiment & News
Key News Insights: ⢠Pediatric data ⢠Leadership promotion ⢠Investor repositioning Arcutis advanced its ZORYVE pediatric program with new Phase 2 and long-term pediatric data and multiple AAD presentations while strengthening leadership amid mixed investor repositioning.
AI Summary
Arcutis has meaningfully shifted from a binary R&D bet to a commercial growth story as ZORYVE is now the nearâterm cash engine, but the investment hinges on sustaining prescription-driven revenue and controlled grossâtoânet/receivable collectionsâmonitor sequential quarterly cashâflow positivity, grossâtoânet trends, and pediatric sNDA progress as triggers that will validate upside or, conversely, signal dilution risk if they deteriorate.
Description
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company developing topical treatments for dermatological conditions. Its lead asset is a roflumilast cream that has completed Phase III trials for plaque psoriasis and atopic dermatitis, and its pipeline includes additional roflumilast and topical JAK1 inhibitor formulations targeting scalp and skin disorders such as seborrheic dermatitis, hand eczema, vitiligo and alopecia areata. The company was incorporated in 2016, changed its name in October 2019, and is headquartered in Westlake Village, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 4 | Mar 11 | ARQT | Arcutis Biotherapeutics, Inc. | Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels. | Closed | -0.7% |
| Dec 2 | Dec 9 | ARQT | Arcutis Biotherapeutics, Inc. | Compelling short-term growth supported by strong Q3 revenue growth (+122% YoY), recent FDA pediatric approvals, upcoming Phase 2 topline data in Q1 2026, solid profitability trends, strong liquidity with $191M cash, and a 20% price surge with bullish technical momentum. | Closed | +1.1% |